Allergan receives FDA approval for Durysta (bimatoprost implant) the first and only intracameral biodegradable sustained-release implant to lower intra-ocular pressure in open-angle glaucoma or ocular hypertension patients

Allergan

5 March 2020 - Durysta lowered intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension by approximately 30% from baseline in two Phase 3 studies.

Allergan today announced that the U.S. FDA has approved the company's new drug application for Durysta (bimatoprost implant) 10 mcg for intracameral administration. 

With this approval, Durysta becomes the first intracameral, biodegradable sustained-release implant indicated to reduce intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension.

Read Allergan press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US , Device